Tier 2 — strong

Effects of N-acetylcysteine on aging cell and obesity complications in obese adults: a randomized, double-blind clinical trial

Mohammad Hassan Sohouli, Ghazaleh Eslamian, Nasser Malekpour Alamdari, Maryam Abbasi, Sepideh Fazeli Taherian, Diba Behtaj, Hamid Zand
Front Nutr 2023 10:1237869

Bibliography

PubMed
PMID 37794966
PubMed Central
PMC10546057
DOI
10.3389/fnut.2023.1237869
Funding
Funding details were not stated in the indexed abstract; consult the full publication for the complete funding disclosure.
Competing interests
The authors declared the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman
Sample40 adults with obesity awaiting bariatric surgery
InterventionNAC 600 mg/day versus placebo
Duration4 weeks
EndpointsAnthropometrics; Insulin resistance; Inflammatory markers; Visceral adipose senescence markers; Lipids

What the study showed, in plain terms

Short randomized trial testing NAC in adults with obesity before bariatric surgery.

Key findings

NAC improved several insulin-resistance, inflammatory and adipose senescence markers but did not significantly change anthropometric measures or lipid profile.

What this study can and cannot tell us

Only 40 participants and four weeks of treatment; metabolic and cellular findings do not establish NAC as a weight-loss supplement.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology